Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines. Circulation. 2018;2019(139):e1082–143.

Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.

Article  PubMed  Google Scholar 

Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and Cardiovascular Risk Reduction among different therapeutic interventions: a systematic review and Meta-analysis. JAMA. 2016;316:1289–97.

Article  CAS  PubMed  Google Scholar 

Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.

Article  CAS  PubMed  Google Scholar 

Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol. 2020;8:36–49.

Article  PubMed  Google Scholar 

Cholesterol Treatment Trialists’ (CTT), Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.

Article  PubMed Central  Google Scholar 

Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396:1637–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical outcomes in patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713–22.

Article  CAS  PubMed  Google Scholar 

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097–107.

Article  CAS  PubMed  Google Scholar 

Sayed A, Shazly O, Slipczuk L, Krittanawong C, Baloch F, Virani SS. The clinical efficacy and safety of Bempedoic Acid in patients at elevated risk of Cardiovascular Disease: a Meta-analysis of Randomized clinical trials. Cardiovasc Drugs Ther. 2023.

Cholesterol Treatment Trialists’ (CTT), Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–405.

Article  Google Scholar 

Kato ET, Cannon CP, Blazing MA, Bohula E, Guneri S, White JA, et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (improved reduction of outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc. 2017;6:e006901.

Article  PubMed  PubMed Central  Google Scholar 

Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279–89.

Article  PubMed  Google Scholar 

De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Ž, Rydén L, et al. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–46.

Article  PubMed  Google Scholar 

Nelson AJ, Haynes K, Shambhu S, Eapen Z, Cziraky MJ, Nanna MG, et al. High-intensity statin use among patients with atherosclerosis in the U.S. J Am Coll Cardiol. 2022;79:1802–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cannon CP, De Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of lipid-lowering therapies over 2 years in GOULD, a Registry of patients with atherosclerotic Cardiovascular Disease in the US. JAMA Cardiol. 2021;6:1060.

Article  PubMed  Google Scholar 

Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II. Atherosclerosis. 2017;266:158–66.

Article  CAS  PubMed  Google Scholar 

Ellins EA, Harris DE, Lacey A, Akbari A, Torabi F, Smith D, et al. Achievement of European Society of Cardiology/European Atherosclerosis Society lipid targets in very high-risk patients: influence of depression and sex. PLoS ONE. 2022;17:e0264529.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Russo G, Pintaudi B, Giorda C, Lucisano G, Nicolucci A, Cristofaro MR, et al. Age- and gender-related differences in LDL-Cholesterol Management in outpatients with type 2 diabetes Mellitus. Int J Endocrinol. 2015;2015:957105.

Article  PubMed  PubMed Central  Google Scholar 

Schoen MW, Tabak RG, Salas J, Scherrer JF, Buckhold FR. Comparison of adherence to Guideline-based cholesterol treatment goals in men Versus Women. Am J Cardiol. 2016;117:48–53.

Article  PubMed  Google Scholar 

De Smedt D, De Bacquer D, De Sutter J, Dallongeville J, Gevaert S, De Backer G, et al. The gender gap in risk factor control: effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. Int J Cardiol. 2016;209:284–90.

Article  PubMed  Google Scholar 

Kim B-K, Hong S-J, Lee Y-J, Hong SJ, Yun KH, Hong B-K, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400:380–90.

Article  CAS  PubMed  Google Scholar 

Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27:593–603.

Article  PubMed  Google Scholar 

Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial. Atherosclerosis. 2021;320:122–8.

Article  CAS  PubMed  Google Scholar 

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after Acute Coronary syndromes. N Engl J Med. 2015;372:2387–97.

Article  CAS  PubMed  Google Scholar 

Aygun S, Tokgozoglu L. Comparison of Current International guidelines for the management of Dyslipidemia. J Clin Med. 2022;11:7249.

Article  PubMed  PubMed Central  Google Scholar 

Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–61.

Article  CAS  PubMed  Google Scholar 

Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of Statin Adherence with mortality in patients with atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019;4:206–13.

Article  PubMed  PubMed Central  Google Scholar 

Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J. 2021;42:243–52.

Article  CAS  PubMed  Google Scholar 

Giral P, Neumann A, Weill A, Coste J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J. 2019;40:3516–25.